Alkem Labs to Acquire 51-55% Stake in Occlutech for €180.70 Mn
Alkem MedTech will acquire a 51-55% stake in Occlutech Holding AG for €180.70 million (Rs. 19,516 million). The transaction is expected to close by June 2026. This strategic move aims to expand Alkem MedTech's presence in the global cardiovascular market. The company also provided updates on its Orthopedics segment, targeting significant implant growth.
The acquisition of a substantial stake in Occlutech, a global player in cardiac devices, represents a major strategic move with significant implications for Alkem Laboratories' future business diversification and market position.
The announcement details a significant strategic acquisition and expansion into the MedTech sector, which is viewed positively for future growth.
Alkem Laboratories Limited announced an updated investor presentation detailing the strategic way forward for Alkem MedTech. The presentation was made available on February 18, 2026.
Alkem MedTech, the company's foray into the MedTech space, is considered a natural progression for expansion, targeting the global MedTech market projected to reach $870 billion by 2030. The company has identified Orthopedics and Cardiovascular as its two priority segments for global presence. In the Orthopedics segment, Alkem MedTech has achieved significant milestones, including CE Approval for Knee & Hip products expected in Q4 FY28 and CIS Country approval in Q1 FY28. They aim for a 5-year vision of launching Knee products in Q2 FY27 and Hip products in Q4 FY27, with a target of 10% market share in India's Large Joints market and over 250,000 implants in five years.
For the Cardiovascular business, Alkem MedTech plans to expand its portfolio through an acquisition of an established global cardio asset. This strategic move is solidified by the announcement that on February 13, 2026, Alkem MedTech executed a binding term sheet for a strategic investment, resulting in the acquisition of a 51-55% stake in Occlutech Holding AG. The total equity value for this acquisition is €180.70 million (Rs. 19,516 million). This transaction is expected to be completed by June 2026, subject to regulatory approvals. Occlutech is a leading player in the structural heart occluder market, ranking #2 in Europe and #3 globally, with a complete portfolio of minimally invasive cardiac devices. The acquisition will be funded through internal accruals and existing cash balances.
Alkem Laboratories Limited, a leading Indian pharmaceutical player, reported revenues of ₹129,645 million in FY24-25 and an EBITDA of ₹25,122 million in the same period. The company has a significant global footprint with operations in over 40 countries.
What to do with a filing like this
Alkem Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under acquisition. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Alkem Laboratories Limited. Read the original for the full detail.